The MTD Group is proud to announce that its “G34 pen needle” device for insulin injection has received the highest award in the #LifeScienceExcellenceAwards 2022 contest, being selected among the top 5 in the category “Best Innovative Device-Technology of the Year” in Italy.
The LSEA award is one of the most influential awards given for the most innovative biomedical technologies, molecules, and prevention, research, and advocacy projects of the past year in the medical science world, thus rewarding companies that have contributed to excellence and innovation in the life science sector.
“This is a further recognition for MTD’s unbroken commitment to improving the life of patients with diabetes” said Carlo Romeo, MTD’s Chief Marketing Officer, who was presented with the prize”; the excellence of our technology has been voted by healthcare professionals, including pharmacists and professional diabetes educators, who have greatly contributed to determining its success” he concluded.